Business
Notice of Results
Notice of Results.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 2174V Faron Pharmaceuticals Oy 05 April 2019 \n\n \nFaron Pharmaceuticals Ltd\n(\"Faron\" or the \"Company\")\n \nNotice of Full Year Results\n \nTURKU - FINLAND, 5 April 2019 - Faron Pharmaceuticals Ltd (\"Faron\") (AIM: FARN), the clinical stage biopharmaceutical company, will announce its full year audited results for the year ended 31 December 2018 on Tuesday 7 May 2019.\n \nDr Markku Jalkanen, Chief Executive Officer, and Yrjö Wichmann, Chief Financial Officer, will host a presentation and conference call for analysts at 9.30am BST on the day of the results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF. Please contact Consilium Strategic Communications for further details.\n \nENDS\n \nFor more information please contact:\n \nFaron Pharmaceuticals Ltd\nDr Markku Jalkanen, Chief Executive Officer\[email protected] \n \nConsilium Strategic Communications\nMary-Jane Elliott, David Daley, Lindsey Neville\nPhone: +44 (0)20 3709 5700\nE-mail: [email protected]\n \nPanmure Gordon (UK) Limited, Nomad and Broker\nEmma Earl, Freddy Crossley (Corporate Finance)\nJames Stearns (Corporate Broking)\nPhone: +44 207 886 2500\n \nWestwicke Partners, IR (US)\nChris Brinzey\nPhone: 01 339 970 2843\nE-Mail: [email protected]\n \n \nAbout Faron Pharmaceuticals Ltd \n \nFaron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company's first candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (\"RAAA\"). Faron's second candidate Clevegen is a ground breaking early clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Turn-on-your-Immunity or Turn-It may be used alone or in combinati...